GLP-1 Drugs Linked to GI Effects, Uncertain Signals - Takeaway - MDSpire
From the Journals

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.

Share

  • 1

    GLP-1 RAs evaluated in 60 meta-analyses across 1,751 trials.

  • 2

    High associations with gastrointestinal events: nausea, vomiting, diarrhea.

  • 3

    Decreased odds of serious infections and respiratory disease.

  • 4

    Methodological concerns affect evidence reliability.

  • 5

    Funding provided by the National Natural Science Foundation of China.

  • 6

    Lead author: Dr. Kaijie Yang from the National Health Commission.

Original Source(s)

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Why Extraction Still Matters in Food Analysis

Ahead of ExTech 2026, Hans-Gerd Janssen weighs in on the challenges and evolution of sample preparation

Diabetes Self-Care Declines During Breast Cancer Treatment

Patients experience reduced monitoring, emotional distress, and gaps in coordinated care during adjuvant therapy

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.